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Background: Autoimmune hepatitis (AIH) is a chronic liver disease caused by inflammation of the liver. The
etiology of AIH remains elusive, and there are no reliable serum biomarkers.
Methods: In order to identify candidate biomarkers, 2-DE analysis of serum proteins was performed using a mouse
model of AIH induced by treatment with concanavalin A (ConA). To enrich samples for low abundance molecules a
commercial albumin removal reagent was used. In an independent analysis, candidate biomarkers were identified
in AIH patient’s serum by a targeted iTRAQ (isobaric tags for relative and absolute quantification) identification.
Candidates were validated in independent cohorts of ConA treated mice and AIH patients by ELISA (enzyme-linked
immuno sorbent assay).
Results: Nine proteins were differentially expressed in AIH mice treated with con-A. Two of these, the third
component of complement (C3) and alpha-2-macroglobulin (A2M) were also up-regulated in AIH patient’s sera by a
targeted iTRAQ identification. In separate validation studies, serum C3 and A2M levels were increased in mice with
ConA treatment after 20-40 h and in 34 AIH patients in a subgroup analysis, females with AIH aged 20–50 years old
displayed the largest increases in serum A2M level. Biological network analysis implements the complement
cascade and protease inhibitors in the pathogenesis of AIH.
Conclusion: The serum proteins C3 and A2M are increased both in a mouse model and in patients with AIH by
both 2-DE and iTRAQ methods. This integrated serum proteomics investigation should be applicable for
translational researchers to study other medical conditions.
Keywords: Autoimmune hepatitis, Serum proteomics, Isobaric tags for relative and absolute quantification (iTRAQ)Background
Autoimmune hepatitis (AIH) is a chronic liver-specific
disease, characterized by elevated aminotransferase levels,
autoantibodies, increased γ-globulin or IgG levels and bi-
opsy evidence of interface hepatitis [1,2]. The etiology of
AIH is not completely understood at present, which
makes it difficult to diagnose [3]. The clinical diagnosis
still depends on the exclusion of other causes of chronic
hepatitis and use of an international scoring system that
includes epidemiologic, biochemical, histological and sero-
logic criteria [4-6].* Correspondence: zizi2006@scu.edu.cn
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reproduction in any medium, provided the orIn clinical examinations, these autoantibodies, includ-
ing anti-nuclear antibodies, anti-smooth muscle anti-
bodies, antibodies to liver-kidney-microsome type 1 and
antibodies to liver cytosol type 1, are used to distinguish
subtypes of AIH. However these antibodies are not spe-
cific to AIH as they are also found in sera from patients
with viral hepatitis, drug-induced hepatitis, or other
autoimmune diseases [7]. Therefore, special biomarkers
for the diagnosis of AIH are still urgently needed.
In the past years, several groups have applied various
approaches to look for potential markers for AIH. Scien-
tists have found some candidate biomarkers for AIH by
proteomics tools. For example, a heterogenous nuclear
ribonucleoprotein A2/B1 (hnRNP-A2/B1) has been iden-
tified as an autoantigen in type 1 AIH (AIH-1) by im-
mune proteomics for the first time [8]. Similarly,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zyme B are also identified as candidate autoantigens in
Chinese patients with AIH [3,9]. Tahiri et al. demon-
strated liver arginase, HSP60, HSP70, HSP90 and
valosin-containing protein represent potential targets on
liver membrane for autoantibodies in AIH-1 by im-
munofluorescence microscopy [10]. In a recent study,
the chip technology was widely used in identification of
biomarkers [6,11]. Six autoantigens (IL4R, AL137145,
LOC646100, C17orf99, METRNL, APCDD1L) were spe-
cifically recognized by AIH sera [11]. In addition, sero-
logical biomarkers were screened from recombinant
cDNA expression libraries. And several molecules, such
as lamin, histone, cyclin A and U1RNP-A, have been
identified as autoantigens in AIH [12].
However, the discrepancy and non-specificity in previ-
ous reports are obvious for these candidate antigens,
which are probably due to the limitations in sensitivity
and accuracy for different approaches. For example, heat
shock proteins (HSPs), differentially expressed in AIH
[13,14] are usually overexpressed in many human
cancers and are implicated in tumor cell proliferation,
differentiation, invasion and metastasis [13,14]. Espe-
cially, several HSPs, including HSP27 and HSP70
etc., are implicated with the prognosis of specific
cancers. In addition, the individual differences of AIH
patients also result in diverse identifications of poten-
tial biomarkers.
In order to overcome discrepancy of different analyt-
ical methods, as well as understand the pathogenesis of
AIH, we adopted a comprehensive serum-based proteo-
mics strategy to look for serological molecules, especially
relative to autoimmune characterization in AIH. The ap-
plication of proteomics to discovery of serum bio-
markers is very active and promising for AIH at present.
However, serum proteomics presents tremendous tech-
nical challenges, with its vast dynamic range in protein
concentrations spanning at least ten of orders of magni-
tude and their dominance by a relatively small number
of highly abundant proteins with about 20 proteins con-
stituting 99% of the entire protein content of serum [15].
So far it is challenging to look for low abundance bio-
markers by serum proteomics analysis. Our studies in-
clude a comparative serum proteome profiling on AIH
mouse models and a targeted iTRAQ (isobaric tags for
relative and absolute quantification) quantitative prote-
omic validation for sera from AIH patients, and subse-
quently complement C3 (C3) and alpha-2-macroglobulin
(A2M) are both identified to associate with AIH in
mouse model and patient’s serum. The potential sero-
logical molecules will provide new viewpoints for under-
standing AIH. This integrated serum proteomics
investigation based on AIH animal models and patient’s
sera can overcome discrepancy in samples and analyticaltools, which provides a complementary means to look
for potential AIH biomarkers.
Results
Mouse model with autoimmune hepatitis
We first successfully developed a mouse model with
AIH by concanavalin A (ConA) treatment. The patho-
logical evidences demonstrated that this model had
characterization of AIH [16,17]. In addition, abnormally
high levels of alanine transarninase (ALT) also showed
that hepatocytes had been damaged. In the AIH mouse
model, the serum levels of ALT in mouse were elevated
significantly after ConA injection for 20 h (n = 6, p < 0.01)
(Figure 1A), and livers from ConA-induced hepatitis mice
exhibited inflammatory cell infiltration, congestion and
dilatation of blood vessel, as well as widespread hepatocel-
lular necrosis in liver lobules (Figure 1B/C). Also patho-
logical changes of hepatic portal vein had been observed
on tissue sections obviously.
Removal efficiency of serum high-abundant proteins
Due to the extensive source, rich value of application,
serum proteomics has important clinical applications on
screening diagnostic markers. However, serum albu-
min can constitute about 50-70% of the total serum
proteins and IgG is up to 10-25%. It is the high
abundance of serum albumin and IgG that are main
drawback of a comprehensive analysis of body fluids.
The presence of these high-abundant proteins can
mask some low-abundant proteins and cause loss of
resolution in 2-DE [18].
After depletion of serum high-abundant proteins by
using the ProteoExtract™ Albumin/IgG Remove Kit,
more than 80% of serum albumin was removed from
serum as monitored by analysis of stained bands on
SDS-PAGE (Figure 2). And the aggregation of human
serum albumin (HAS), IgG heavy chain and IgG light
chain was greatly reduced. The AIH mouse sera with de-
pletion of high-abundant proteins were run 2-DE, and
the treated sera from AIH patients were performed
iTRAQ analysis.
Differential serum expressing profiling in 2-DE gel
The differential serum expression profile between AIH
mice and controls was compared by 2-DE. Several differ-
ently expressed proteins were enlarged to show in
Figure 3. The experiments were repeated three times
independently. Only reproducibly detected spots
with statistical significance were subjected to mass
spectrum (MS) analysis. A total of 9 proteins displayed
marked alterations and were successfully identified by
MS/MS between AIH and control sera (±over 1.5-fold,
p < 0.05) (Table 1).
Figure 1 The characterization of a mouse model with autoimmune hepatitis. The serum ALT levels (A) and histological examination of liver
tissues (B-C) were shown. The ALT levels were elevated in serum at 20 h after ConA treatment for BALB/c mice (n = 6, **p < 0.01). The hepatic
vein showed pathological changes obviously (arrow indications) in liver biopsy of AIH mice (B), while the hepatic portal vein and hepatic lobule
are clear in normal mouse liver (C).
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average number of unique peptides identified by MS/MS
was 3.2, and the average value of Mascot score was 66.
Among them, interleukin 17 F and vitamin D-binding
protein precursor were down-regulated in AIH, while
other 7 proteins were up-regulated. Most altered pro-
teins belong to immune or hepatitis related proteins. In
the increased proteins, serum amyloid A1 (SAA-1) and
serum amyloid A2 (SAA-2) are acute phase lipoproteins
rapidly produced in the liver with trauma or infection,
and the serum amyloid proteins potently enhance cyto-
kine production from peripheral blood mononuclear
cells. In our data the SAA-1 and SAA-2 were indentified
to increase with the highest degree, which is also sup-
ported that SAA has a high correlation with hepatitis
[19]. Prior studies have shown that the serum concentra-
tions of alpha-fetoprotein, variably elevated during liver
injury, have been suggested to be of prognostic import-
ance in acute liver failure [20]. Similarly, Kuo et al.
found a marked elevation of serum alpha-fetoprotein
with severe jaundice as an initial manifestation of AIH[21]. The fumarylacetoacetase, which was also identified
to be upregulated in our AIH mice, was also verified by
its autoantibody in sera of a mouse hepatitis model [22].
The findings brought into correspondence with our ex-
perimental result which showed an increase in AIH
model compared to the control group.
However, we paid attention to two up-regulated pro-
teins C3 and A2M, tightly associated with immune re-
sponse in autoimmune inflammation. Although these
two proteins were not altered with a largest degree, in
order to validate their relative expression levels in pa-
tient’s serum with AIH, a targeted iTRAQ analysis as a
proof-of-principle experiment was performed to exam-
ine the expression of C3 and A2M in AIH patient’s
serum as following.
The iTRAQ-based validation for two proteins in patient’s
serum
As a proof-of-concept investigation, the altered serum
proteins C3 and A2M in AIH mouse were further veri-
fied their expression levels in AIH patient’s serum by a
Figure 2 Removal efficiency of serum high-abundant proteins.
40 μl of healthy human plasma was processed with the
ProteoExtractTM Albumin Remove reagent. 50 μg protein from each
fraction was separated by SDS-PAGE and visualized by silver staining.
The aggregation of HAS (A); IgG heavy chain (B) and IgG light chain
(C) was greatly reduced. P: human plasma, R: plasma without
high-abundant proteins.
Figure 3 The spots with differential expression level between AIH an
changed. The spot 1–7 was up-regulated in AIH mouse serum, while the sp
spot 1–9 was respectively identified as following, including SAA2, SAA1, AF
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was elucidated in Figure 4. The differential expression
level between normal and AIH serum was determined
via the peak intensity ratio of iTRAQ-labeling peptides
with a mass tag (m/z116, m/z114).
Consistent with 2-DE results in AIH mouse, the C3
and A2M were also identified to increase in patient’s
serum with AIH by iTRAQ analysis (Figure 5). The pep-
tides identified by iTRAQ were listed in the Table 2. For
example, the peak intensity of a peptide containing
“LVAYYTLIGASGQR” sequences in protein C3 was 713
and 239 counts corresponding to the 116 and 114 re-
agent labeling serum (AIH serum versus normal serum).
Therefore, the differential expression level of C3 was
2.98-fold upregulation in AIH patient’s serum compared
with the normal human serum in first time iTRAQ ana-
lysis. Among these isotope labeling peptides of C3, the
isotope peptides “531LVAYYTLIGASGQR544” was specif-
ically derived from C3 β chain, one of breakdown prod-
ucts of C3. And this pair of peak intensity ratio was 2.9
(116 versus 114), which mainly contributed to the in-
creased level of C3 in serum. Further, the antibody for
ELISA analysis was raised against peptides mapping near
the N-terminus of human C3, allowing for detection of
the beta-chain in both the uncleaved C3 precursor pro-
tein and a cleaved product C3b. Similarly, the 116/114
mass containing peptide intensity ratio was 1.68 (346/
206 = 1.68) in the A2M, which indicated that it was in-
creased in AIH serum. These two kinds of methods
showed a high degree of consistency.Serum levels of C3 and A2M in AIH mice measured by
ELISA
In order to validate different levels of C3 and A2M in
normal conditions and pathological disease with AIH,
their serum levels were dynamically detected in AIH
model mice. Female BALB/C mice, 6–8 weeks old, were
used to establish animal models with AIH. Mice serum
samples were collected at different time points afterd normal mouse sera. Spots labeled with the arrow were significantly
ot 8–9 was significantly decreased. The protein corresponding to the
P, C3, GPX4, FAH, A2M, IL17F and GC.
Table 1 Differentially expressed proteins identified by 2-DE










1 serum amyloid A2 SAA2 acute phase reactant gi6755394 13613.5/6.41 122 2 ↑6.56 ± 0.2 N/Af
2 serum amyloid A1 SAA1 acute phase reactant gi404753 13691.5/6.5 45 2 ↑14.72 ± 2.1 N/A
3 alpha-fetoprotein AFP estrogens, fatty acids
and metals binding
gi191765 47194.9/5.47 172 7 ↑3.00 ± 0.9 N/A






gi2673845 22290.59/6.74 54 3 ↑4.16 ± 0.18 N/A
6 fumarylacetoacetase FAH enzyme regulator
activity; protein
binding
gi253320 46416/6.56 43 4 ↑12.4 ± 0.78 N/A
7 alpha-2-macroglobulin A2M activation immune gi110347469 167144/6.17 41 3 ↑1.98 ± 0.23 1.61
8 interleukin 17 F IL17F actin/ vitamin D
binding





gi51172612 53565/5.39 56 3 ↓2.08 ± 0.2 N/A
aTheoretical molecular weight (kDa) and pI from the ExPASy database.
bProbability-based Mascot scores.
cNumber of unique peptides identified by MS/MS.
dAverage expression level of altered proteins by 2-DE and MS from three independent analyses (mean ± SD) (↑,increased; ↓, decreased).
eThe differential expression of proteins in serum from AIH patients and controls was validated by iTRAQ (average of the two experiments, control: 114; AIH: 116).
fN/A, Not analyzed by iTRAQ.
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At each treatment time point, 6 mice were used as a
group to detect serum protein level compared with a
standard curve, and each serum sample was detected in
triplicate. In the control group without ConA treatment,
serum C3 and A2M was in a lower level, with 12.16 ±Figure 4 The serum proteome analysis of a mouse model with autoim
clinical serum. The pooled serum samples were depleted of albumin and
were used for the subsequent differential expression analysis. Serum protei
serum by 2-DE, differential proteins were identified by MS/MS. On the othe
iTRAQ reagents to perform LC-MS/MS, and the target proteins were selecte
iTRAQ quantification.3.67 mg/dl for C3 and 1.19 ± 0.69 mg/dl for A2M. While
serum level of C3 and A2M was ascended sharply to
19.79 ± 6.13 mg/dl and 4.45 ± 1.8 mg/dl after ConA
treatment for 20 h, and their serum concentration was
not changed significantly in the next two treatment time
points of 30 h, 40 h (Figure 6).mune hepatitis by 2-DE and a targeted iTRAQ validation on
IgG using ProteoExtract Albumin Removal Kit, and protein fractions
n expression profile of AIH mice was compared with normal mouse
r hand, the AIH patient’s serum was pretreated and labeled with
d to validate their expression levels in AIH patient’s sera by
Figure 5 Representative MS/MS spectra of iTRAQ-labeling peptides derived from C3 and A2M. For each MS/MS spectrum, b- and y-type
fragment ions enable peptide identification, whereas the intensity counts of peak areas for each of the iTRAQ signature ions enable quantification
of the peptides and proteins. A, MS/MS spectra of the peptide “LVAYYTLIGASGQR” from complement C3β. B, MS/MS spectra of the peptide
“AIGYLNTGYQR” from A2M. The pair of reporter ions (m/z116 and m/z114) was highlighted in the enlarged inset map.
Table 2 The peptides of C3 and A2M were identified by iTRAQ analysis
Protein name Peptide sequence Ion scorea Peptide ratio
(116/114)b
Protein ratio (116/114)c











bThe peptides of C3 and A2M were identified by iTRAQ analysis (Control: 114; AIH: 116).
cThe differential expression of C3 and A2M in serum between AIH patients and controls was calculated based on the isotope labeling peptides.
d Peptide “531LVAYYTLIGASGQR544” is a part of C3β chain.
Peptide “1172AGDFLEANYMNLQR1185” is a part of C3d fragment.
Peptide “363YFKPGMPFDLMVFVTNPDGSPAYR386” is a part of C3β chain.
Peptide “1354DQLTCNK1360” is a part of C3c α chain fragment 2.
Peptide “905TGLQEVEVK913” is a part of C3c α chain fragment 1.
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Figure 6 Serum Levels of C3 and A2M in AIH mice with ConA
treatment for different times. In each group, six mice were
treated with ConA from 0–40 h (n = 6). *P <0.05, **P < 0.01 (AIH
mouse serum versus control serum). Data were shown with the
mean value and SD.
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patients
First, we focused on the general serum level of these two
proteins in 34 AIH patients, which was consistent with
the higher level in AIH mouse models. In 34 AIH pa-
tients, the average value of serum C3 was 210.72 ±
51.43 mg/dl, while the mean value of normal controls
was 156.27 ± 41.83 mg/dl. So the serum C3 was in-
creased in AIH patients compared with normal persons
(p<0.01). Among the 34 AIH cases, serum C3 level was
increased in 25 AIH samples (73.5%) compared to the
normal controls, and 5 samples (15%) were no obvious
differences between AIH and control group (Table 3).
However, C3 level was lower in other 4 cases (11.8%) of
AIH serum than normal human donors. Similarly, the
average value of serum A2M in AIH patients was
161.45 ± 91.49 mg/dl, which was higher than the average
level 102.94 ± 44.03 mg/dl in normal persons (p<0.01).
Among the 34 AIH samples, serum A2M level was in-
creased in 21 AIH patients (61.8%), 4 cases (11.8%) had
similar levels between AIH and control group. There
were also 9 cases (26.4%) of AIH with lower serum A2M
level than normal persons.Table 3 The serum level of C3 and A2M were compared
between AIH and control group
Relative serum levela
Increased Little changed Decreased
Protein name Sample cases (%) b
C3 25 (73.5%) 5 (14.7%) 4 (11.8%)
A2M 21 (61.8%) 4 (11.8%) 9 (26.4%)
a Compared with the control group, the level of the protein in AIH group.
b Sample cases and the percentage of the cases compared with the total.Subsequently, we classified serum samples according
to patient’s gender and age (Additional file 1: Table S1),
and serum C3 and A2M levels were further analyzed be-
tween male and female patients in different age groups.
As shown in Figure 7A, there were markedly elevated
levels of serum C3 and A2M in AIH persons than
healthy donors in the age range of 20–70 years. It was
noted that serum A2M level in female AIH patients was
higher than the male ones from 20–60 years (p<0.01).
Particularly, in young and middle-aged AIH persons
with 20–50 years, serum A2M level was greatly in-
creased significantly in female group (Figure 7B). Our
results were also supported previous conclusions that
AIH can be found more often in younger patients with
prevalence for females [23].Comparisons of C3 and A2M level in different forms of
hepatitis
Furthermore, serum levels of these two proteins were
measured in other forms of hepatitis, including patients
with hepatitis B and hepatitis C, to primarily validate
their sensitivity and specificity in AIH. As results, com-
pared with 10 cases with hepatitis B or hepatitis C, the
serum C3 and A2M were raised in AIH patients than
healthy persons with significant differences (Figure 7C-D),
while their levels were remained unconspicuous differ-
ences among groups with hepatitis B or hepatitis C, and
healthy controls. So far, the serum levels of C3 and
A2M in AIH patients can directly reflect immunopatho-
logical conditions.Biological network analysis by web-based bioinformatics
analysis
The C3 and A2M were revealed as differentially
expressed between AIH and normal serum validated by
2-DE, iTRAQ and ELISA analysis. In order to analyze
potential roles of the two proteins in inflammatory dis-
ease, the intrinsic interactions with other proteins of C3
and A2M were respectively analyzed using STRING soft-
ware, a web-based protein interaction mapping tool.
In the protein interaction maps, ten proteins including
complement factor H, complement component recep-
tor 2 (CR2), complement factor I all interact with C3
(Figure 8A). The complement cascade and its regulation
by these other proteins have all been described in great
detail. C3 plays a central role in the activation of the
complement system by the classical, alternate, and lectin
pathways. Factor H functions as a co-factor in the in-
activation of C3b by factor I and also increases the rate
of dissociation of the C3bBb complexes. CR2 also reg-
ulates complement activation, serves as a receptor for
iC3b, C3dg, and C3d, and contributes to B lymphocyte
activation [24].
Figure 7 Serum C3 and A2M levels in AIH patients validated by ELISA. A-B. Serum C3 and A2M levels measured based on the gender and age
of AIH patients . (Classified by gender, n = 10 for female control group and n = 16 for female AIH group; n = 9 for male control group and n = 18 for
male AIH group. Classified by age in AIH group, n = 13 for patients with 20–40 years, n = 13 for the group with 41–60 years, and n = 8 for the group
with 61–80 years. For control healthy group, n = 7 for 20–40 years’ group, n = 6 for 41–60 years’ group and n = 5 for 61–80 years’ group). C-D. Serum
C3 and A2M levels measured in patients with different forms of hepatitis. (**P < 0.01 versus control samples, n = 10 for hepatitis B group, n = 10 for
hepatitis C group and n = 19 for control group).
Figure 8 Proteins involved in complement C3 and A2M functions were analyzed using STRING software. The functional partners were
predicted by different methods, which were shown in different line colors (Seen the panels within the figure caption). Blue ( , co-occurrence),
means the presence of linked proteins across species; black ( , coexpression), means the genes co-expressed in the same or in other species;
purple ( , experiments), shows a significant protein interaction from the reports of literatures; light blue ( , database), shows a significant protein
interaction groups gathered from databases; green ( , textmining), shows protein interaction groups extracted from scientific literatures. The
predicted functional partners include as follows. CFH, complement factor H; CR2, complement component receptor 2; CFI, complement factor I;
VSIG4, V-set and immunoglobulin domain containing 4; C3AR1, complement component 3a receptor 1; CR1, complement component (3b/4b)
receptor 1; CD46, CD46 molecule, complement regulatory protein; CFD, complement factor D; C5AR1, complement component 5a receptor 1;
CFB, complement factor B; APP, Amyloid beta (A4) precursor protein; KLKB1, plasma kallikrein; TGFB1, transforming growth factor, beta 1;
SERPINE1, serpin peptidase inhibitor, clade E, member 1; SERPINF2, serpin peptidase inhibitor; ALB, albumin; CTSB, cathepsin B; SERPINA1, serpin
peptidase inhibitor, clade A, member 1; PLG, plasminogen; EGF, epidermal growth factor.
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sociated with other 10 proteins in an immune response
network (Figure 8B). Amyloid beta (A4) precursor pro-
tein and transforming growth factor beta 1 assist A2M
to participate in exocytosis of platelet alpha granule con-
tents. And serpin peptidase inhibitors, clade E and clade
F, are also involved in this process. Another molecule,
plasma kallikrein is significant for the counterbalance of
plasma renin angiotensin system which may mediate ef-
fects on the immune response in autoimmune inflam-
mation [25,26].
Discussion
In this study, we had applied a comprehensive serum
proteomics strategy to look for important differential
proteins in serum based on AIH mouse model and pa-
tient’s serum. And totally 9 altered proteins were identi-
fied in AIH mice serum by 2-DE. Two upregulated
proteins, C3 and A2M, were validated in the serum of
AIH patients by a targeted iTRAQ analysis. And further-
more, serum level of C3 and A2M was generally higher
in 34 cases of AIH patients than normal persons by
ELISA detection. From mouse models to clinical AIH
sera, the integrated serum proteomics investigation can
overcome discrepancy in samples and tools, which is a
translational medical viewpoint to look for the molecules
associated with AIH.
Serum proteome contains the proteins not only from
the liver, small intestine synthesis such as albumin, but
also millions of species of immunoglobulin. The serum
proteome holds the promise of a reform in disease diag-
nosis and therapeutic monitoring provided that major
challenges in proteomics and related disciplines can be
addressed [15,27]. The iTRAQ-based quantitative prote-
omics can offer a discovery of more accurate differences
of expression between different samples. Based on the
initial attempt to analyze the patient’s serum with AIH
by iTRAQ method, more potential biomarkers will be
found in latter systematically identification on multiple
serum samples.
Autoantibodies make a major contribution to the diag-
nosis of autoimmune diseases, and immunoproteomics
provides a wide range of application for AIH research.
So there are many studies to look for autoantibody-
based biomarkers. On the perspective of specific
autoantigens, comprehensive serum proteomics strategy
has been used to look for differential proteins in AIH.
Beside the potential diagnostic value, the discovery of
novel AIH autoantigens could provide insights on im-
munopathological conditions and pathogenicity mechan-
ism of this disease. In our study, several proteins were
identified to increase in AIH serum, which had been
reported in other previous studies. For example, it has
reported that the elevation of AFP level can be causedby autoimmune hepatitis [21]. And this protein AFP was
also identified to increase to 3 times in AIH mouse
serum in our analysis. So far, our work could provide
some values for identification of specific autoantigens of
AIH through a translational medical strategy coupled
with an integrated proteomic approach.
On the other hand, the C3 and A2M both belong to
inflammatory and immune-relative molecules. C3 is an
acute phase reactant of the complement system that rep-
resents a crucial effector of the acute phase response of
innate immunity. Excessive complement activation and
abnormal serum levels of C3 and A2M have been impli-
cated in the pathophysiology of various inflammatory dis-
eases [28-30], including AIH, systemic lupus erythematosus
(SLE) [31], diabetes [32], and anorexia nervosa [30], etc. In
order to primarily validate the sensitivity and specificity of
C3 and A2M in AIH, serum levels of these two proteins
were measured in other forms of hepatitis, including 10 pa-
tients with hepatitis B or hepatitis C. Therefore, serum
levels of C3 and A2M can serve as markers of some disease
activity, even a potential biomarker in relation to diagnosis
for the disease severity.
In our investigation, the C3 level was identified to in-
crease in AIH serum. Activation of the complement sys-
tem is involved in the pathogenesis of the systemic
autoimmune diseases [29]. C3 plays an important role in
the activation of the complement system. The C3 lies in
the central position to interact other complement com-
ponents from our bioinformatics analysis. The up-
regulation of C3 and its interacting network suggest that
it plays an important role in the development of AIH.
Therefore, the change quantification of C3 level in AIH
patient’s serum is key to understand the alterations that
biological systems undergo. Recent studies have demon-
strated that complement contributes to the development
of autoimmune diabetes [33,34]. Also reports showed
that complement could play a pivotal role in liver spe-
cific autoantibody, which mediated hepatocyte injury
in AIH, and that complement inhibitors could be, in
principle, developed as novel therapeutics against
AIH [35].
A2M levels and change patterns in AIH patient’s
serum can differ greatly between males and females, al-
though generally its concentration in AIH is significantly
higher than normal human serum (Figure 7B). In fact,
the serum A2M level is usually different between man
and woman in normal physiological conditions [28],
which partially brings about more complexity in level
changes in immunopathological conditions. Similarly,
this difference of A2M level is also associated with age
and sex in diabetes [32]. Furthermore, serum A2M level
is significantly increased in patients with hepatic fibrosis
that is the final common pathway of liver injury in most
liver diseases [36]. Therefore, accurate quantification for
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disease progression.
In summary, we profiled proteome alterations between
AIH and control samples based on two complementary
proteomics methods including 2-DE and iTRAQ. Totally
9 altered proteins were identified in AIH mouse sera by
2-DE MS/MS, furthermore the C3 and A2M were vali-
dated to increase in mice model and AIH patient’s sera
via iTRAQ and ELISA analysis. Further studies in large
samples are needed to demonstrate the specificity, sensi-
tivity and mechanism of C3 and A2M in the diagnosis
and pathogenesis of AIH.
Materials and methods
Mouse model with autoimmune hepatitis
The following animal experiments were approved by
the Institutional Animal Care and Use Committee of
Sichuan University, which was also in compliance with
all regulatory guidelines.
Female BALB/C mice, 6–8 weeks old, were purchased
in the West China Medical Center of Sichuan University
(Chengdu, China) to establish AIH models. 24 female
BALB/C mice were equally classified into four groups
randomly and labeled AIH groups respectively with
ConA treatment for 20 h, 30 h and 40 h, and a control
group was injected with physiological saline. The mice
of AIH groups were injected intravenously via caudal
vein with 15 mg/kg ConA (Sigma, USA). Mouse serum
was collected from caudal vein after ConA treatment for
20 h to determine ALT level using an automated enzyme
assay (Roche Diagnostics GmbH, Mannhein, Germany).
And the liver tissues were harvested for histological
examination. The experiment of mouse models with
AIH was performed 3 repeats.
AIH patient’s serum
The diagnosis of AIH was made at west China Hospital
of Sichuan University according to the criteria defined
by the International AIH Group. The Committee on
Medical Ethics of West China Hospital approved the fol-
lowing procedures. The venous sera from 34 AIH pa-
tients, including 18 males and 16 females (Additional
file 1: Table S1), without any drug treatment, were col-
lected from West China Hospital, Sichuan University
(Chengdu, P. R. China) with the offers’ informed con-
sent. Normal control sera were obtained from 19 healthy
donors (9 males and 10 females) whose gender were
matched with the AIH subjects. In addition, in order to
compare protein level in other forms of hepatitis, 10
human serum samples were respectively collected from
patients with hepatitis B and hepatitis C.
All serum samples were collected and processed
according to standard operating procedures to minimize
pre-analytical variation [37]. About 3 ml of venous bloodwas collected into vacutainer tubes (vacutainer plus
blood collection tube; Becton Dickinson), allowed to clot
for 1 h at 37°C and centrifuged at 2000 g 4°C for
10 min. Serum was then frozen immediately at −80°C.
The concentrations of the pooled sera were determined
with the Bradford method using bovine serum albumin
as a standard.Depletion of high-abundance serum proteins
Sera (except hemolysis) were collected from the mouse
model or patients with AIH and clotted for 2 h at room
temperature. The clotted material was removed by cen-
trifugation at 3000 rpm for 15 min.
In order to enhance the resolution, the main high-
abundant proteins were removed from serum using the
ProteoExtract™ Albumin Removal column (ProteoExtract™
Albumin Removal Kit; Calbiochem, San Diego, CA). 40 μl
of sera was processed with one removal column for each
time, and the depletion procedures were performed at
room temperature according to manufacturer’s instruc-
tions. The collected samples were further concentrated by
precipitation using 4 × volume of ice-cold acetone.2-DE
The 2-DE was performed as described previously [18].
One hundred micrograms of the mice serum protein,
high-abundance deprived, were suspended in lysis buffer
(7 M urea, 4% CHAPS, 60 mM DTT, 2% BioLyte 4–7
(BioRad)) for the isoelectric focusing (IEF) analysis on a
17 cm long IPG (immobilized pH gradient) strips (pH4-7)
(Bio-Rad). After IPG strips were rehydrated at 50 V for
12 h, IEF was performed at 20°C with a constant power
(50 μA/ IPG-strip) at 250 V for 30 min, linear; 1000 V for
1 h, rapid; linear ramping to 10000 V for 5 h; and finally
10000 V for 6 h. Before the second dimension, the IPG
strips were equilibrated in solution A (50 mM Tris–HCl
(pH 8.8), 6 M urea, 20% glycerol, 2% SDS and 10 mM
DTT) for 15 min, washed with solution B (50 mM Tris–
HCl (pH 8.8), 6 M urea, 20% glycerol, 2% SDS, and
200 mM iodoacetamide) for another 15 min. The IPG
strip was transferred onto 12% SDS-PAGE gel to separate
for second-dimension.
Gels were fixed in 45% ethanol and 5% acetic acid for
2 h, washed with water for 20 min twice, and then incu-
bated in the sensitization solution containing 0.02% so-
dium thiosulfate for 2 min. After washing with water for
5 min for 3 times, gels were stained in a solution
containing 0.1% silver nitrate for 30 min at 4°C. Protein
spots were developed in a solution with 2% (w/v) sodium
carbonate and 0.04% formaldehyde until spots were
clearly visible. Then 1% acetic acid was applied to
stop development, finally gels underwent three times
of 5-min washes in water.
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Gel images were acquired with Bio-Rad GS-800 scanner
under white lights (400–750 nm). Image analysis of the
protein spots was performed using the PDQuest software
8.0.1 (Bio-Rad). Detection, normalization and matching of
protein spots were automatically performed and manually
confirmed. For statistical analysis, student’s t-test (p < 0.05)
was performed to compare data from the three repeated
experiments. Only such spots that showed consistent and
significant differences (over 1.5-fold, p < 0.05) were selected
for following MS identification.
In-gel digestion and MS/MS identification
In-gel digestion of proteins was carried out by using
MS-grade trypsin (Promega). Excised spots were cut to
about 1-2 mm diameter by using a disposable scalpel
and destained by using 50% acetonitrile (ACN) / 50%
50 mM ammonium bicarbonate solution, followed by
dehydration in 100% ACN for 15 min. Then each sample
was incubated with 10 ng/μL MS-grade trypsin solution
overnight at 37°C. Tryptic digests were extracted, and
concentrated in a vacuum concentrator at room
temperature for MS analysis [38].
As for ESI-Q-TOF MS analysis, the automatic scan
rate was 1.0 s with an interscan delay of 0.02 s, and the
system was operated at 3.0 kV. Spectra were accumu-
lated until a satisfactory signal/noise (S/N) ratio had
been obtained. Parent mass peaks with m/z from 400 to
1600 were selected for MS/MS analysis. The collision
energy was chosen to vary between 18 and 57 eV de-
pending on the mass of the precursor.
Data acquisition was performed with MassLynx V4.1
(Micromass) software with automated data processing by
the proteinlynx V2.25 software provided with the Waters
Corporation. The PKL files were analyzed by the
MASCOT search engine (http://www.matrixscience.com).
The search parameters were defined as follows: Database,
Swiss-Prot 57.2 (466739 sequences; 165389953 residues);
taxonomy, mus musculus; enzyme, trypsin; and allowance
of one missed cleavage. Carbamidomethylation was se-
lected as a fixed modification and oxidation of methionine
was allowed to be variable. The fragment mass toler-
ance was set at ± 0.3 Da, respectively. Only proteins
with at least one peptide exceeding their score thresh-
old (p < 0.05), and with the molecular weight and pI
consistent with the gel regions from which the spots were
excised, were considered to be positively identified.
Protein isobaric labeling with iTRAQ reagents
The iTRAQ labeling was performed according to the
manufacturer’s protocol (Applied Biosystems) after
desalting by acetone precipitation and depletion of abun-
dant proteins. Each type of iTRAQ labeling was
performed with 100 μg serum proteins, which weremixed from sera of 3 AIH patients or 3 healthy samples
(gender matched). The iTRAQ experiment was performed
on two groups for two times. One group of AIH patients
included 1 male and 2 females, and another group
contained 2 males and 1 female. In each time, the pooled
samples were divided into two aliquots (AIH and control
group). For blocking cysteine residues, each sample was
added with reagents as sequence: 25 μL sample buffer
(1 M triethylammonium bicarbonate, TEAB); 1 μL of the
denaturant (2% SDS); 2 μL reducing reagent (50 mM
tris-(2-carboxyethyl) phosphine, TCEP). The samples
were incubated at 60°C for 1 h, and then 1 μL of a
freshly prepared 84 mM iodoacetamide solution was
added to treat in the dark at room temperature for
30 min.
The proteins were then digested overnight at 37°C
with 10 μl of 1 μg/μl trypsin solution (Trypsin Gold,
Promega, Madison). And they were labeled with one iso-
baric amine-reactive tag as following, control sample:
iTRAQ Reagent 114; AIH: iTRAQ Reagent 116. The la-
beled peptides were then mixed and dried. Finally, the
pooled iTRAQ-labeled peptide samples were desalted
prior to strong cation exchange (SCX)-chromatographic
fractionation and LC-MS/MS analysis using a Q-TOF
mass spectrometer (Micromass, Manchester, UK), fitted
with an ESI or MALDI source (Micromass) coupled with
LC Packings Ultimate microcapillary LC system (Dionex,
Sunnyvale, CA, USA) [39].
Database search and iTRAQ quantification
The protein identification and quantification by iTRAQ
were achieved using MassLynx Module 4.1 software
(Micromass) and MASCOT search engine. The MAS-
COT searches were run by the following parameters:
database, NCBInr 20111206 (16,392,747 sequences;
5,641,810,382 residues); taxonomy, Homo sapiens; en-
zyme, trypsin; fixed modifications, carbamidomethyl(C),
iTRAQ 4plex (N-term), iTRAQ 4plex (K); variable mod-
ifications, Oxidation (M), iTRAQ4plex (Y); MS/MS tol-
erance as 0.3 Da; Instrument type, ESI-QUAD-TOF.
Results were scored by using the probability-based score
(the ions score is 10 × log (P), where P is the probability
that the observed match is a random event), and protein
scores are derived from ions scores as a non-probabilistic
basis for ranking protein hits.
Protein expression quantification was performed based
on iTRAQ data from MS/MS scans, which was displayed
as the ratio of peak areas between m/z 114 and 116 Da.
The ratios from raw data sets were used to calculate fold
changes between control and AIH samples.
The MS raw data for peptide quantification were
processed and analyzed by the MassLynx Module 4.1
software. The results were then exported into Excel for
manual data interpretation. Generally, most of the
Li et al. Journal of Translational Medicine 2013, 11:146 Page 12 of 13
http://www.translational-medicine.com/content/11/1/146protein ratios in the quantification data are close to 1.0
in iTRAQ analysis,the protein ratio lies between 0.785
and 1.275 for almost 95% of the proteins, which indicates
that ratios outside these limits are likely to be due to bio-
logical, rather than technical variation in a test versus
control experiment [40]. Therefore, in order to get more
accurate data, proteins were usually considered up-
regulated or down-regulated when their ratios were >1.3
or <0.7 [41,42]. The error factor (EF) and the 95% confi-
dence interval (95% CI) were calculated for each protein.
We set ratios over 1.3 or below 0.7 as statistically signifi-
cant changes in iTRAQ analysis, with EF < 2 and p <0.05.
The median ratio was calculated for each labeling.
Serum C3 and A2M quantification by ELISA
In ELISA analysis, serum samples were collected from
AIH mice at sequential time points after ConA treat-
ment for 20-40 h. The levels of C3 and A2M in serum
were quantified using an ELISA assay (Human/Mouse
C3 ELISA kit (E90861Hu/E90861Mu); Human/Mouse
A2M ELISA kit (E91017Hu/E91017 Mu), USCNK Life
Sciences Inc., Wuhan, China) according to the manufac-
turer’s instructions.
Similarly, serum C3 and A2M levels were also verified
in 34 AIH patients, 10 patients with hepatitis B or hepa-
titis C, and 19 healthy donors by ELISA. The procedures
on human serum were fully approved by the Institu-
tional Review Board of West China Hospital.
The data were reported as means ± SD. Statistical sig-
nificance was assessed by unpaired, two-tailed Student’s
t-test when comparing two groups. p < 0.05 was consid-
ered statistically significant.
Biological network analysis with the STRING software
Biological network analysis of C3 and A2M was
performed using a web-based software STRING (http://
string-db.org). This software STRING aims to analyze data
on protein-protein interactions. We queried the inter-
active network of C3 and A2M with a medium confidence
and no more than 10 interactors. The resulting network
was presented with a summary of the predicted functional
links for the protein, ranked by estimated confidence.
Additional file
Additional file 1: Table S1. The serum information from AIH patients
in ELISA examination.
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